Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389532 · ClinicalTrials.gov registry record · Phase 4
Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 116
- Enrollment target
NCT00389532 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 116 participants.
The verdict
NCT00389532, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 116 participants
- Enrollment target
Study Summary
To submit remaining available sera to Center for Biologics Evaluation and Research (CBER) for further analysis by the Food and Drug Administration (FDA), the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to support selection and recommendation of antigen strains for subsequent influenza vaccines.
Interventions
- BIOLOGICAL Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389532
The ClinicalTrials.gov registry entry for NCT00389532 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine (2006-2007 Fluzone® vaccine) is the first listed.
NCT00389532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389532 about?
NCT00389532 is a clinical study titled "Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine". To submit remaining available sera to Center for Biologics Evaluation and Research (CBER) for further analysis by the Food and Drug Administration (FDA), the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to support selection and recommendation of antigen str...
What is the current status of trial NCT00389532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2006-10. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00389532?
The interventions under investigation include: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00389532?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.